Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver, usually occurring in patients with chronic liver disease, particularly those with cirrhosis or chronic HBV infection. About 75% of primary liver tumors are HCC, while the rest are mostly cholangiocarcinoma.
Liver cancer and intrahepatic cholangiocarcinoma rank as the 6th most common cancers globally. In 2020, approximately 900,000 new cases were reported. Primary liver cancer is the 3rd leading cause of cancer-related deaths worldwide, with more than 830,000 deaths in 2020. The 5-year survival rate of liver cancer is about 21%, making it one of the deadliest gastrointestinal tumors.
Liver cancer has a higher incidence in parts of Asia and Africa, especially in countries such as China, Vietnam, and Egypt, often caused by hepatitis B virus and hepatitis C virus infections. With improvements in public health, some developed countries show relatively lower incidence, but significant regional differences remain worldwide.
The incidence of HCC varies across regions. It is estimated that 72% of HCC cases occur in Asia, with Europe, Africa, North America, and Latin America accounting for 10%, 8%, 5%, and 5% respectively. Mongolia has the highest incidence of liver cancer (93.7/100,000), but China has the largest number of cases due to both high incidence (18.3/100,000) and a large population. The variation in HCC prevalence is likely related to differences in exposure to hepatitis viruses and environmental pathogens. HCC occurs more frequently in males, with a male-to-female ratio of approximately 3:1.
1. Liver Function Impairment
Liver cancer invades normal liver tissue, leading to progressive liver failure, manifested as jaundice, ascites, and other symptoms, severely affecting quality of life.
2. Tumor Metastasis Risk
Liver cancer is prone to hematogenous and lymphatic metastasis, commonly involving the lungs, bones, and lymph nodes, which increases treatment difficulty and shortens survival.
3. Severe Complications
Advanced liver cancer is often accompanied by complications such as gastrointestinal bleeding and hepatic encephalopathy, making treatment difficult and disease progression rapid.
Immune reconstruction cell therapy activates the patient’s immune system to effectively identify and eliminate liver cancer cells, enhancing the body’s anti-tumor ability. This therapy has advantages such as low side effects and repeatability, making it an important complement to comprehensive treatment.
① Activates T cells and natural killer cells, improving immune surveillance;
② Reduces immunosuppressive tumor microenvironment, improving treatment response;
③ Enhances quality of life and slows disease progression.
In clinical practice, cancer patients undergoing surgery, radiotherapy, or chemotherapy often face immune dysfunction, increased risk of infection, and slow recovery. To support patients through treatment, improve tolerance, and enhance survival quality, it is necessary to develop scientifically phased immune reconstruction plans for different treatment cycles.
● Short-term Plan: Rapidly boost immunity through immune cell transfusion to enhance anti-cancer treatment effects.
● Mid-term Plan: Reduce side effects of traditional treatments, promote recovery, and ensure completion of standard therapies.
● Long-term Plan: Strengthen overall immunity through immune cell reconstruction, gut immune restoration, elemental immune support, and immune nutrition rebuilding, improving quality of life and extending survival.
1. Surgical Resection
Surgery is the curative treatment for early-stage liver cancer, suitable for patients with good liver function and localized tumors. Tumor resection can significantly extend survival but requires good liver function.
2. Local Ablation
Including radiofrequency ablation and microwave ablation, it is suitable for patients who cannot undergo surgery or those with early-stage small tumors. It is minimally invasive, with quick recovery, making it an important micro-invasive treatment.
3. Transarterial Chemoembolization (TACE)
Delivers chemotherapy drugs and embolic agents directly into the tumor-feeding artery via catheter to inhibit tumor growth, commonly used for intermediate and advanced-stage patients.
4. Targeted Therapy
Targeted drugs against tumor molecular mechanisms can slow cancer progression and improve prognosis in some patients, especially those in advanced stages.
Liver cancer progresses rapidly and is extremely harmful, requiring active treatment. Experts from United Life International Medical Center emphasize that immune reconstruction cell therapy offers new treatment options for liver cancer patients. When combined with conventional treatments, it can significantly improve prognosis and extend survival. Early diagnosis and treatment are key to improving outcomes.
